海天天線(08227.HK)附屬進一步出售208萬股中科雲網 獲利27萬人幣
海天天線(08227.HK)公布,自去年12月24日起,已通過全資附屬公司於深圳證券交易所及通過證券交易商進一步出售了中科雲網股份(002306.SZ)合共208萬股,總代價為575萬元人民幣。
公司指,在考慮中科雲網之財務表現及天線產品銷售及提供相關服務經營分部之營運資金需求後,並鑑於進一步出售事項乃按照及參考現行市價進行,董事認為,進一步出售事項乃按正常商業條款進行,屬公平合理,並符合公司及股東之整體利益。
公司又指,預計進一步出售事項將導致截至2021年12月31日止財政年度投資收益約27萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.